| Postmarketing Experience Adverse drug reactions from spontaneous reports during the worldwide postmarketing experience with Pancrelipase Capsules that meet threshold criteria are included in Table 1. The adverse drug reactions are ranked by frequency, using the following convention:Very common  1/10 Common 1/100 and < 1/10 Uncommon 1/1,000 and <1/100 Rare 1/10,000 and <1/1,000 Very rare <1/10,000, including isolated reportsThe frequencies provided below reflect reporting rates for adverse drug reactions from spontaneous reports, and do not represent more precise estimates that might be obtained in clinical trials or epidemiological studies.The most frequently reported adverse events were of gastrointestinal origin i.e. nausea, vomiting and diarrhoea.Table 1. Postmarketing reports of adverse drug reactions | Metabolism and Nutrition Disorders | Very rare | weight decrease | | | Investigations | Very rare | hyperuricosuria, hyperuricaemia | | | Gastrointestinal disorders | Very rare | abdominal distention, abdominal pain, abnormal faeces, colonic stenosis, diarrhoea, intestinal bleeding, perianal irritation, dyspepsia, fibrosing colonopathy, flatulence, ileal stenosis, intestinal obstruction, melaena, nausea, constipation, vomiting. | | | General disorders and administration site conditions | Very rare | oedema, pain, | | | Skin and subcutaneous tissue disorders | Very rare | pruritus, rash | | |
| |